Rosiglitazone enhances glucose uptake in glomerular podocytes using the glucose transporter GLUT1

AIMS/HYPOTHESIS: Peroxisome proliferator-activated receptor (PPAR) γ agonists are used increasingly in the treatment of type 2 diabetes. In the context of renal disease, PPARγ agonists reduce microalbuminuria in diabetic nephropathy; however, the mechanisms underlying this effect are unknown. Glomer...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Diabetologia
Egile Nagusiak: Lennon, R., Welsh, G.I., Singh, A., Satchell, S.C., Coward, R.J., Tavaré, J.M., Mathieson, P.W., Saleem, M.A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2009
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7614273/
https://ncbi.nlm.nih.gov/pubmed/19533082
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00125-009-1423-7
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak